Q3 2023 · 13F-HR
CAXTON CORPholdings as filed
Filed 2023-11-14 · accession 0000919574-23-006304
$26.3M
Reported value
9
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 805111101 | SVRA | SAVARA INC | $12.5M | 47.6% | 3,313,602 | Common | SOLE |
| 98422E103 | XERS | XERIS BIOPHARMA HOLDINGS INC | $10.5M | 39.9% | 5,641,920 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $1.7M | 6.61% | 1,318,967 | Common | SOLE |
| 608550208 | MTEMEUR | MOLECULAR TEMPLATES INC | $864,993 | 3.29% | 136,866 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $265,653 | 1.01% | 12,472 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $170,942 | 0.65% | 86,773 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $133,387 | 0.51% | 19,473 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $111,978 | 0.43% | 49,329 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $14,453 | 0.05% | 21,813 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.